NCT07193901CompletedPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
A Randomized, Double-blind, Placebo-controlled Phase Il Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to learn about: * To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior * To evaluate the safety and pharmacokinetic (PK) characteristics after multiple dose of PRT-042 nasal spray in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (actual)
- First submitted
- 1 Sept 2025
- Start date
- 27 May 2025
- Primary completion date
- 10 Apr 2026
- Lead sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
- Diseases
- Depression
- NCT number
- NCT07193901
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 98
- From 27 May 2025 to the primary completion date, 10 Apr 2026
- 15 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features .
- Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder, within the 6 months before screening
- Participant has a current or prior diagnosis of a reatment resistant depression
- Previous participation in another clinical trial and receiving the investigational drug within 3 months prior to dosing.
Other illness
- Participant has a current DSM-5 diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder.
- Participant has a current clinical diagnosis of autism, dementia, or intellectual disability.
- Any nasal conditions or diseases that, in the investigator's judgment, may significantly affect the administration or absorption of a nasal product.
- Participant has a history of malignancy within 5 years before screening
Other
- Pregnant or breastfeeding women, or those with a positive pregnancy test result during screening.
Who the study is looking for
- Participant must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI) .
- Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 \[Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?\] and Question B10 \[Intend to act on thoughts of killing yourself?\] obtained from the MINI.
- Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (≥) 28 and the score for item 10"suicide ideation" of greater than (≥) 3 predose on Day 1
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Sixth Hospital of Peking University Coordinator of this site? Confirm its status | Beijin | China | Unknown status |
| Beijing Anding Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing Huilongguan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Brain Hospital of Hunan Province Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| The Second Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| The Fourth People's Hospital of Chengdu Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Hangzhou Seventh People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| The fourth affiliated hospital of Anhui medical university Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center) Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| The Affiliated Hospital of Southwest Medical University Coordinator of this site? Confirm its status | Luzhou | China | Unknown status |
| The First Affiliated Hospital of NanChang University Coordinator of this site? Confirm its status | Nanchang | China | Unknown status |
| The Affiliated Kangning Hospital of Ningbo University Coordinator of this site? Confirm its status | Ningbo | China | Unknown status |
| Suzhou Guangji Hospital Coordinator of this site? Confirm its status | Suzhou | China | Unknown status |
| Wuxi Mental Health Center Coordinator of this site? Confirm its status | Wuxi | China | Unknown status |
| Zhumadian Second People's Hospital(Zhumadian Psychiatric Hospital ) Coordinator of this site? Confirm its status | Zhumadian | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.